Tag: corticosteroids
Outcomes of Different Steroid Dosing Regimens in Critical Covid-19 Pneumonia
The study found that high-dose steroids in the treatment of critically ill patients with COVID-19 pneumonia did not confer any mortality benefit and were associated with an increased risk of dysglycemia and superimposed infections. A... read more
The Existence of Adrenal Insufficiency in COVID-19 Patients with Pneumonia
Patients with a history of COVID-19 pneumonia who present with clinical symptoms such as shock, nausea, vomiting, and fatigue should have hypocortisolism included in the differential diagnosis. These patients should also... read more
Dexamethasone Systemic Effects in Severe COVID-19
Dexamethasone is the standard of care for critically ill patients with COVID-19, but the mechanisms by which it decreases mortality and its immunological effects in this setting are not understood. Here we perform bulk... read more
Hydrocortisone, Ascorbic Acid, and Thiamine Combination Therapy Efficacy for the Management of Sepsis and Septic Shock
In this systematic review, we found that hydrocortisone, ascorbic acid, and thiamine (HAT) regimen may be useful for reducing the duration of vasopressor use and improve organ functions in patients with sepsis and septic... read more
Proposal for a 4-Level Classification System of Severe COPD Exacerbation According to Healthcare Resource Utilization
The definition of an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD) has been modified several times the last decade in Global Initiative for COPD (GOLD) recommendations. According to the updated GOLD... read more
Risk Factor for Superimposed Nosocomial BSI in Hospitalized COVID-19 Patients
Unmodified risk variables for nosocomial bloodstream infections (BSIs) included male sex and leukocytosis at admission. Using methylprednisolone and obtaining a cumulative dosage of dexamethasone were adjusted risk variables... read more
Effect of P2Y12 Inhibitors on Organ Support-Free Survival in COVID-19 Patients
n this randomized clinical trial of critically ill participants hospitalized for COVID-19, treatment with a P2Y12 inhibitor did not improve the number of days alive and free of cardiovascular or respiratory organ support.... read more
Optimal Bundle of Recommendations for Sepsis
The aim of this retrospective cohort study was to identify among the Surviving Sepsis Campaign (SSC) guidelines the optimal bundle of recommendations that minimize 28-day mortality. The bundle of six recommendations is... read more
Surfactant Therapies for Pediatric ARDS
We advocate for well-designed preclinical and explanatory clinical studies to investigate the use of surfactant for pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome. Given the accumulating knowledge... read more
Etomidate, Adrenal Insufficiency and Mortality Associated with Severity of Illness
Whereas etomidate causes adrenal insufficiency, it was not shown to increase mortality in many analyzed here in ICU settings. However, etomidate associated relative mortality rates increased progressively and correlated with... read more
Co-infection and ICU-acquired Infection in COVID-19 ICU Patients
In patients with severe COVID-19 in the first wave, co-infection at admission to ICU was relatively rare but antibiotic use was in substantial excess to that indication. ICU-AI were common and were significantly associated... read more
Baricitinib in COVID-19 Patients
In patients hospitalized with COVID-19, baricitinib significantly reduced the risk of death but the size of benefit was somewhat smaller than that suggested by previous trials. The total randomized evidence to date suggests... read more
Obstructive Airway Diseases: Role of Lipid Mediators
Incidences of inflammatory airway diseases are on the rise across the world. Existing therapeutic options are ineffective, unsafe, and expensive, and severe cases are nonresponsive to conventional therapy. Therefore, it is... read more
Association Between Dexamethasone Treatment for COVID-19 Patients and Rates of Hospital Readmission and Mortality
Current guidelines recommend use of dexamethasone, 6 mg/d, up to 10 days or until discharge for patients hospitalized with COVID-19. Whether patients who received less than 10 days of corticosteroids during hospitalization... read more
Inhaled Corticosteroid Use on COVID-19 Outcomes Among Hospitalized Adult Asthmatics
While our findings confirm trends observed by others with respect to risk factors among asthmatics with COVID-19, differences based on sex, ethnicity and ICS use in asthmatics were observed. Our finding that ICS use was associated... read more
The Role of Antiviral Treatment in the COVID-19 Pandemic
US Food and Drug Administration (FDA) issued an emergency use authorisation for Pfizer's COVID-19 antiviral, Paxlovid few weeks ago. Trial results released by the manufacturer indicate that the drug cuts the risk of hospitalisation... read more
WHO Recommends Two New Drugs for COVID-19 Treatment
WHO has recommended two new drugs for COVID-19, providing yet more options for treating the disease. The extent to which these medicines will save lives depends on how widely available and affordable they will be. The... read more
Efficacy of Inhaled Ciclesonide for Outpatient Treatment with Symptomatic COVID-19
The results of this randomized clinical trial demonstrated that ciclesonide did not achieve the primary efficacy end point of reduced time to alleviation of all COVID-19–related symptoms. A total of 413 participants... read more
Biomarker-guided Steroid Dosing in COVID-19 Pneumonia
Although corticosteroid administration has been associated with improved outcomes in severe COVID-19 pneumonia, their ideal use remains undefined with a "one size fits all" approach used, irrespective of the individual inflammatory... read more
Prescription Rates Changes for Inhaled Corticosteroids During the COVID-19 Pandemic
During the COVID-19 pandemic, despite early concerns the impact oral corticosteroids might have on the effects of acute COVID-19 reported by the WHO and the potential severity of disease in patients with asthma and chronic... read more
Effect of High vs. Low Dose of Dexamethasone on COVID-19 Pneumonia Patients
Among hospitalised COVID-19 patients needing oxygen therapy, high dose of dexamethasone reduced clinical worsening within 11 days after randomisation as compared with low dose of dexamethasone. Further studies are necessary... read more
Safety and Efficacy of MUST-ARDS
This important first study, using multipotent adult progenitor cells in ARDS patients (MUST-ARDS), was a phase 1/2 randomised, blinded, placebo-controlled trial that demonstrated safety and tolerability of intravenous administration... read more
